Zevra Therapeutics Inc’s filing revealed that its President and CEO McFarlane Neil F. unloaded Company’s shares for reported $0.21 million on Oct 10 ’25. In the deal valued at $10.82 per share,19,500 shares were sold. As a result of this transaction, McFarlane Neil F. now holds 222,016 shares worth roughly $1.96 million.
Then, NEIL F MCFARLANE bought 19,500 shares, generating $210,990 in total proceeds.
Before that, FAVORITO TAMARA A bought 3,175 shares. Zevra Therapeutics Inc shares valued at $24,718 were divested by the Director at a price of $7.79 per share. As a result of the transaction, FAVORITO TAMARA A now holds 3,894 shares, worth roughly $34306.14.
H.C. Wainwright initiated its Zevra Therapeutics Inc [ZVRA] rating to a Buy in a research note published on July 02, 2025; the price target was $26. Guggenheim began covering ZVRA with “Buy” recommendation on October 07, 2024. Maxim Group maintained its rating on September 24, 2024. It rated ZVRA as “a Buy”.
Price Performance Review of ZVRA
On Tuesday, Zevra Therapeutics Inc [NASDAQ:ZVRA] saw its stock fall -0.11% to $8.81. Over the last five days, the stock has gained 3.04%. Zevra Therapeutics Inc shares have risen nearly 2.92% since the year began. Nevertheless, the stocks have risen 5.64% over the past one year. While a 52-week high of $13.16 was reached on 07/15/25, a 52-week low of $6.19 was recorded on 04/09/25.
Levels Of Support And Resistance For ZVRA Stock
The 24-hour chart illustrates a support level at 8.62, which if violated will result in even more drops to 8.44. On the upside, there is a resistance level at 8.96. A further resistance level may holdings at 9.12.
How much short interest is there in Zevra Therapeutics Inc?
A steep rise in short interest was recorded in Zevra Therapeutics Inc stocks on 2025-12-15, dropping by -0.85 million shares to a total of 6.89 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 7.73 million shares. There was a decline of -12.28%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on September 24, 2024 when JMP Securities began covering the stock and recommended ‘”a Mkt outperform”‘ rating along with a $17 price target.
